AUA 2022 | Durvalumab monotherapy for patients with BCG-unresponsive carcinoma-in-situ bladder cancer
Roger Li, MD, Moffitt Cancer Center, Tampa, FL, discusses an investigator-initiated Phase II study (NCT02901548) of durvalumab monotherapy for patients with Bacillus Calmette-Guerin (BCG)-unresponsive carcinoma-in-situ of the bladder. 17 patients were enrolled in the trial and the primary endpoint was complete response rate (CRR) at 6 months. The 3-month CRR was 40% and was comparable to previously reported results from immune checkpoint blockade monotherapy from the KEYNOTE-057 and SWOG trials. The 6-month CRR was 11% and the trial has since been terminated due to futility. This interview took place at the American Urological Association annual congress 2022 in New Orleans and online.
Disclosures
Research support: Predicine; Decipher Biosciences. CG Oncology.
Clinical trial protocol committee – CG Oncology;
Scientific advisor/consultant – BMS, Ferring, Fergene, Arquer Diagnostics, Urogen Pharma, Lucence.
